pcDNA3.3_SARS2_omicron BA.2 Citations (8)
Originally described in: Broadly neutralizing antibodies target the coronavirus fusion peptide.Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW, Kosik I, Hu Z, Zhao M, Mohan D, Cooper AJR, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Drawbaugh D, Eaton B, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Holbrook MR, Nemazee D, Mascola JR, Wilson IA, Tan J Science. 2022 Jul 12:eabq3773. doi: 10.1126/science.abq3773. PubMed Journal
Articles Citing pcDNA3.3_SARS2_omicron BA.2
Articles |
---|
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. Zhang L, Narayanan KK, Cooper L, Chan KK, Skeeters SS, Devlin CA, Aguhob A, Shirley K, Rong L, Rehman J, Malik AB, Procko E. EMBO Mol Med. 2022 Nov 8;14(11):e16109. doi: 10.15252/emmm.202216109. Epub 2022 Sep 23. PubMed |
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.
Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J.
Cell Host Microbe. 2022 Nov 4. pii: S1931-3128(22)00523-6. doi: 10.1016/j.chom.2022.10.010.
PubMed
Associated Plasmids |
GRP78 Inhibitor YUM70 Suppresses SARS-CoV-2 Viral Entry, Spike Protein Production and Ameliorates Lung Damage. Ha DP, Shin WJ, Hernandez JC, Neamati N, Dubeau L, Machida K, Lee AS. Viruses. 2023 May 6;15(5):1118. doi: 10.3390/v15051118. PubMed |
The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection. Bains A, Guan W, LiWang PJ. Viruses. 2023 Sep 9;15(9):1901. doi: 10.3390/v15091901. PubMed |
Inhibitory Efficacy of Main Components of Scutellaria baicalensis on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II. Lin CH, Chang HJ, Lin MW, Yang XR, Lee CH, Lin CS. Int J Mol Sci. 2024 Mar 2;25(5):2935. doi: 10.3390/ijms25052935. PubMed |
Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens. Ho CL, Yen LC, Huang HW, Lu CC, Hung YJ, Liao CL, Hung CM, Chiu KC. Front Immunol. 2024 Mar 12;15:1340645. doi: 10.3389/fimmu.2024.1340645. eCollection 2024. PubMed |
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Eden T, Schaffrath AZ, Wesolowski J, Stahler T, Tode N, Richter N, Schafer W, Hambach J, Hermans-Borgmeyer I, Woens J, Le Gall CM, Wendler S, Linke-Winnebeck C, Stobbe M, Budnicki I, Wanney A, Heitz Y, Schimmelpfennig L, Schweitzer L, Zimmer D, Stahl E, Seyfried F, Gebhardt AJ, Dieckow L, Riecken K, Fehse B, Bannas P, Magnus T, Verdoes M, Figdor CG, Hartlepp KF, Schleer H, Funer J, Tomas NM, Haag F, Rissiek B, Mann AM, Menzel S, Koch-Nolte F. Nat Commun. 2024 Jun 3;15(1):4728. doi: 10.1038/s41467-024-48735-x. PubMed |
Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2. Connor RI, Sakharkar M, Rappazzo CG, Kaku CI, Curtis NC, Shin S, Wieland-Alter WF, Wentworth J, Mielcarz DW, Weiner JA, Ackerman ME, Walker LM, Lee J, Wright PF. Pathog Immun. 2024 Jun 18;9(2):1-24. doi: 10.20411/pai.v9i2.679. eCollection 2024. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.